Pub. Date : 2011 Jan 30
PMID : 21094153
15 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Studies on the effects of heparin products on pregnancy-associated plasma protein A. | Heparin | pappalysin 1 | Homo sapiens |
| 2 | BACKGROUND: Intravenous low molecular weight (LMWH) and unfractionated heparin (UFH) increase the circulating concentrations of pregnancy-associated plasma protein A (PAPP-A), a novel cardiac risk marker, in haemodialysis and coronary angiography patients. | Heparin | pappalysin 1 | Homo sapiens |
| 3 | BACKGROUND: Intravenous low molecular weight (LMWH) and unfractionated heparin (UFH) increase the circulating concentrations of pregnancy-associated plasma protein A (PAPP-A), a novel cardiac risk marker, in haemodialysis and coronary angiography patients. | Heparin | pappalysin 1 | Homo sapiens |
| 4 | BACKGROUND: Intravenous low molecular weight (LMWH) and unfractionated heparin (UFH) increase the circulating concentrations of pregnancy-associated plasma protein A (PAPP-A), a novel cardiac risk marker, in haemodialysis and coronary angiography patients. | Heparin | pappalysin 1 | Homo sapiens |
| 5 | BACKGROUND: Intravenous low molecular weight (LMWH) and unfractionated heparin (UFH) increase the circulating concentrations of pregnancy-associated plasma protein A (PAPP-A), a novel cardiac risk marker, in haemodialysis and coronary angiography patients. | Heparin | pappalysin 1 | Homo sapiens |
| 6 | BACKGROUND: Intravenous low molecular weight (LMWH) and unfractionated heparin (UFH) increase the circulating concentrations of pregnancy-associated plasma protein A (PAPP-A), a novel cardiac risk marker, in haemodialysis and coronary angiography patients. | Heparin | pappalysin 1 | Homo sapiens |
| 7 | BACKGROUND: Intravenous low molecular weight (LMWH) and unfractionated heparin (UFH) increase the circulating concentrations of pregnancy-associated plasma protein A (PAPP-A), a novel cardiac risk marker, in haemodialysis and coronary angiography patients. | Heparin | pappalysin 1 | Homo sapiens |
| 8 | The interaction between heparin products and free PAPP-A was studied with gel filtration. | Heparin | pappalysin 1 | Homo sapiens |
| 9 | RESULTS: After intravenous UFH and LMWH free PAPP-A increased significantly but bivalirudin had no effect. | Heparin | pappalysin 1 | Homo sapiens |
| 10 | After LMWH bolus in haemodialysis patients 85% of free PAPP-A was cleared with a half-life of 13.1 min and the rest with a half-life of 96.6 min. | Heparin | pappalysin 1 | Homo sapiens |
| 11 | Subcutaneous LMWH led to lower and slower free PAPP-A elevation. | Heparin | pappalysin 1 | Homo sapiens |
| 12 | PAPP-A extracted from plaque tissues was in free form and extraction was strongly enhanced by LMWH. | Heparin | pappalysin 1 | Homo sapiens |
| 13 | Heparin products increased the molecular size of free PAPP-A. | Heparin | pappalysin 1 | Homo sapiens |
| 14 | CONCLUSIONS: The heparin-induced PAPP-A elevation is seen in various patients and should be taken into account when PAPP-A is studied as a biomarker. | Heparin | pappalysin 1 | Homo sapiens |
| 15 | CONCLUSIONS: The heparin-induced PAPP-A elevation is seen in various patients and should be taken into account when PAPP-A is studied as a biomarker. | Heparin | pappalysin 1 | Homo sapiens |